Another soft launch, page-5

No way it is a soft launch this time around. Some comments from recent announcements and reports:. If you're ever feeling swayed by the constant negativity of some, just refer back to May's Presentation and concentrate on the following:

 First licensing revenues underway & expected to build through 2017
 OBJ expects increasing revenue based upon P&G’s revenue guidance
 Licensed products (microarray) now being distributed by P&G
 Two additional microarray products licensed to P&G ready for distribution, two more under development  Second technology licensed to P&G & expected to be commercialised over next 18 months
 Successful Bodyguard clinical trial completed at UQ – Japanese manufacturer engaged. Distribution discussions with three parties in different markets/market segments
 Two Accelerators in discussions to fund OBJ’s technologies in conjunction with P&G

I don't know of too many R&D companies on the ASX with so much on their plate and within months of significant on-going revenues.